An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy. The VECTRA Study
STP938-301
Phase 1 other active
Quick answer
An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy. The VECTRA Study for Thrombocythaemia is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Thrombocythaemia
- Phase
- Phase 1
- Modality
- other
- Status
- active